15 October 2013Asia

Bayer takes another swipe at Nexavar compulsory licence

Bayer has appealed against the Indian Intellectual Property Appellate Board (IPAB)’s compulsory licence (CL) order that allows domestic generic maker Natco Pharma to market its own version of liver and kidney cancer drug Nexavar, this time at the Mumbai High Court.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk